An expert discusses how chronic hand eczema (CHE) presents in various clinical and etiologic subtypes, including irritant and allergic contact dermatitis, atopic hand eczema, and protein contact dermatitis, with clinical manifestations ranging from hyperkeratotic to vesicular forms.
An expert discusses how chronic hand eczema (CHE) is a common condition affecting 1% to 5% of adults and is defined as hand eczema lasting at least 3 months or relapsing at least 2 times per year, distinct from atopic dermatitis.
In this interview, Chovatiya and Shahriari highlight notable elements of the upcoming Revolutionizing Atopic Dermatitis (RAD) Conference.
Revolutionizing Atopic Dermatitis 2025 Annual Meeting cochair Raj Chovatiya, MD, PhD, previews the upcoming meeting.
A pair of experts discuss unmet needs and educational gaps related to atopic dermatitis.
In this interview, Chovatiya highlighted the unmet needs of patients with atopic dermatitis and the ways in which nemolizumab’s FDA approval addresses them.
This interview with Chovatiya highlights his portion of the ‘Skin of Color’ talk at the American Academy of Dermatology conference.
This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.
Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.
Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.
Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.
Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.
Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.
Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.
Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.
Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.
Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.
Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.
Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.
Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.
Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.
Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.
After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.
In this episode of MEDcast, expert dermatologists delve into the practical aspects of using photodynamic therapy (PDT) for treatment of actinic keratosis. Specialists are sharing their protocols, advances in PDT delivery, tips for training clinical staff and communicating with patients.
In this episode of MEDcast, expert dermatologists delve into the practical aspects of using photodynamic therapy (PDT) for treatment of actinic keratosis. Specialists are sharing their protocols, advances in PDT delivery, tips for training clinical staff and communicating with patients.
In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.
In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.
In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.
In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.
In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis
